I am the Director of Wolfson Institute of Preventive Medicine and also Head of Centre for Cancer Prevention. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2015) 16(1):67-75. PMID: 25497694
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2014) 383(9922):1041-8. PMID: 24333009
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Onc (2011) 12(3):245-255. PMID: 21310658
A breast cancer prediction model incorporating familial and personal risk factors. Statist Med (2004) 23: 1111-1130. PMID: 15057881
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 362: 1871-1876. PMID: 14667741
I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.
I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.
I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.
Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Kammerer-Jacquet S-F, Ahmad A, Møller H et al. Mod Pathol (2019) 32(2) 1303-1309
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay Soliman H, Flake DDII, Magliocco A et al. JCO Precision Oncology (1)
Screening performance of abbreviated versions of the UPSIT smell test. Joseph T, Auger SD, Peress L et al. J Neurol (2019) 266(2) 1897-1906
Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Brenner A, Afolabi A, Ahmad SM et al. Trials (2019) 20(2) 467
Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Evans DGR, Harkness EF, Brentnall AR et al. Breast Cancer Res Treat (2019) 176(2) 141-148
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Sestak I, Blake GM, Patel R et al. Bone (2019) 124(2) 83-88
Predicting late recurrence in ER-positive breast cancer. Cuzick J Nat Rev Clin Oncol (2019) 16(2) 406-408
Prediction of reader estimates of mammographic density using convolutional neural networks. Ionescu GV, Fergie M, Berks M et al. J Med Imaging (Bellingham) (2019) 6(2) 031405
A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. Brentnall AR, van Veen EM, Harkness EF et al. Int J Cancer (2019) (2)
A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model Brentnall AR, Cohn WF, Knaus WA et al. Journal of Breast Imaging (2019) 1(1) 99-106For additional publications, please click here
I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.
I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.